Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoxetine SCHEMBL8467346 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL570572 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8353 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL33947 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL3905325 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7081402 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8911991 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL17436534 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3399076 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7902048 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| US-20230355553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING OCULAR DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-11-09 | — | — | US | claimed |
| CN-117007693-A | 23 antidepressants and 17 metabolites detection method | 河南中医药大学第一附属医院 | 2023-11-07 | — | — | CN | claimed |
| CN-114605272-B | Preparation method of (R) -fluoxetine and derivatives thereof | 中国科学技术大学 | 2023-09-08 | — | — | CN | claimed |
| US-20220249404-A1 | COMPOSITION CONTAINING FLUOXETINE AND VITAMIN D3 OR ITS DERIVATIVES, AND APPLICATION THEREOF | NANJING RUIYING RUNZE BIOPHARMACEUTICAL TECHNOLOGY CO., INC. (CN) | 2022-08-11 | — | — | US | claimed |
| CN-114605272-A | Preparation method of (R) -fluoxetine and derivative thereof | 中国科学技术大学 | 2022-06-10 | — | — | CN | claimed |
| CN-112007039-B | A pharmaceutical composition containing fluoxetine and vitamin D3Or derivatives thereof, and uses thereof | 南京睿鹰润泽生物医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-7485754-B2 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. (CA) | 2009-02-03 | — | — | US | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | claimed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | claimed |
| US-5068432-A | Amination and etherification of a halo alcohol and resolution of a racemic mixture | ALDRICH CHEMICAL COMPANY, INC. (US) | 1991-11-26 | — | — | US | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4577246-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250177770-A1 | SUBSTANCE USE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | ACTIPULSE NEUROSCIENCE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-0909754-A1 | Process to make chiral compounds | ELI LILLY AND COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0612242-A4 | METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE. | SEPRACOR INC (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0612242-A1 | METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE | SEPRACOR, INC. (US) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING OCULAR DISORDERS | NLRP3, PYCARD, HTRA1 | SLC6A4 345/4885MEN1 4205/4885KMT2A 2339/4885 |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A4 1/4885MEN1 4831/4885KMT2A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.